NASDAQ:ALDX Aldeyra Therapeutics Q1 2026 Earnings Report $1.78 +0.07 (+3.78%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aldeyra Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.13Beat/MissN/AOne Year Ago EPSN/AAldeyra Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAldeyra Therapeutics Announcement DetailsQuarterQ1 2026Date5/13/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Aldeyra Therapeutics Earnings HeadlinesALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Inconsistent Trial Data: Levi & Korsinsky2 hours ago | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aldeyra Therapeutics, Inc. Of Class Action Lawsuit and Upcoming Deadlines – ALDXMay 5 at 5:06 PM | globenewswire.comThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged… Defense stocks exploded…And gold ripped past $5,000.May 6 at 1:00 AM | Behind the Markets (Ad)ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law FirmMay 5 at 2:43 PM | prnewswire.comALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMay 5 at 10:20 AM | globenewswire.comALDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aldeyra Therapeutics (ALDX) Investors of Securities Class Action Deadline on May 29, 2026May 5 at 9:07 AM | prnewswire.comSee More Aldeyra Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aldeyra Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aldeyra Therapeutics and other key companies, straight to your email. Email Address About Aldeyra TherapeuticsAldeyra Therapeutics (NASDAQ:ALDX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need. The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis. Aldeyra is also developing ADX-2191, an intravitreal formulation targeting proliferative vitreoretinopathy, a serious complication of retinal detachment surgery. In addition to its ophthalmology pipeline, Aldeyra has earlier-stage programs exploring systemic indications where reactive aldehyde species contribute to inflammation and tissue damage. Founded in 2009 and headquartered in Lexington, Massachusetts, Aldeyra is led by a management team with extensive experience in ophthalmology and biopharmaceutical development. Under the leadership of Chief Executive Officer Fredric A. Hargreaves, the company collaborates with clinical research centers across North America and Europe to advance its pipeline through late-stage clinical trials. Aldeyra’s strategy emphasizes rigorous clinical validation, strategic partnerships and readiness for commercial launch upon regulatory approval.View Aldeyra Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Years in the Making, AMD’s Upside Movement Has Just BegunPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating SystemGrab Holdings Faces Hurdles, But Upside Potential Is Hard to IgnorePalantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026 Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026)W.W. Grainger (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
